Sentence examples for development of biosafety from inspiring English sources

The article reviews the development of biosafety regulations in the USA and the EU, focussing on diverging concepts applied for assessing the risks of genetically modified organisms (GMOs).

It is interesting to note, but in the light of the above-described historical development of biosafety regulations, it is not surprising that neither the EU, the CBD nor the OECD includes GMO projects and biosafety policies under the scope of SEAs.

We believe that the inclusion of wild animals in control and eradication programmes, and the development of efficient biosafety practices in extensive farms should be a priority to eradicate the disease in livestock.

The United States Agency for International Development (USAID), through the Program for Biosafety Systems, supports the development of biotechnology and biosafety policies.

With the rapid development of nanotechnology, nanomaterials' biosafety has attracted more and more attention [50 56].

During the period 2002-10, FAO undertook an intense activity of biosafety capacity development, largely centred on enhancing the capacities of regulators and other technical staff involved in the implementation of biosafety frameworks, along with other components.

FAO assists its member countries to develop their capacities in agricultural biotechnologies and related issues through technical cooperation and training and provides advice to them on the development of national biotechnology strategies and biosafety frameworks.

To this end, the European Commission initiated the SYNBIOSAFE consortium (http://www.synbiosafe.eu/) focusing on the discussion of biosafety and ethical concerns, and facilitating a socially acceptable development in all related fields.

This approach provides an additional layer of biosafety and thus has great potential for use in the rational development of safer flavivirus vaccines.

However, LASV vaccine development has been hindered by the lack of appropriate small animal models for efficacy evaluation independent of biosafety level four (BSL-4) facilities.

Going into the negotiations, many expected the debate to focus on biosafety, and specifically the development of gene drives.